ALN-AT3SC-003: ATLAS INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B with Inhibitory Antibodies to Factor VIII or IX

Recruiting
99 years or below
All
Phase 3
1 participants needed

Brief description of study

This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with bypassing agents, as determined by the frequency of bleeding episodes in enrolled adult subjects who are who have hemophilia A or B with an inhibitor who are not on prophylaxis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hemophilia
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 830125

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.